Cargando…
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
INTRODUCTION: This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A(2A) receptors (A(2A)R). METHODS: After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570588/ https://www.ncbi.nlm.nih.gov/pubmed/26370839 http://dx.doi.org/10.1186/s13075-015-0771-6 |
_version_ | 1782390222753890304 |
---|---|
author | Perez-Aso, Miguel Montesinos, M. Carmen Mediero, Aránzazu Wilder, Tuere Schafer, Peter H. Cronstein, Bruce |
author_facet | Perez-Aso, Miguel Montesinos, M. Carmen Mediero, Aránzazu Wilder, Tuere Schafer, Peter H. Cronstein, Bruce |
author_sort | Perez-Aso, Miguel |
collection | PubMed |
description | INTRODUCTION: This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A(2A) receptors (A(2A)R). METHODS: After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10, IL-6 and IL-1α were measured in the Raw264.7 monocytic murine cell line. PKA, Epac1/2 (signaling intermediates for cAMP) and A(2A)R knockdowns were performed by shRNA transfection and interactions with A2AR and A2BR, as well as with methotrexate were tested in vitro and in the murine air pouch model. Statistical differences were determined using one or two-way ANOVA or Student’s t test. The alpha nominal level was set at 0.05 in all cases. A P value of < 0.05 was considered significant. RESULTS: In vitro, apremilast increased intracellular cAMP and inhibited TNF-α release (IC(50)=104nM) and the specific A(2A)R-agonist CGS21680 (1μM) increased apremilast potency (IC(50)=25nM). In this cell line, apremilast increased IL-10 production. PKA, Epac1 and Epac2 knockdowns prevented TNF-α inhibition and IL-10 stimulation by apremilast. In the murine air pouch model, both apremilast and MTX significantly inhibited leukocyte infiltration, while apremilast, but not MTX, significantly inhibited TNF-α release. The addition of MTX (1 mg/kg) to apremilast (5 mg/kg) yielded no more inhibition of leukocyte infiltration or TNF-α release than with apremilast alone. CONCLUSIONS: The immunoregulatory effects of apremilast appear to be mediated by cAMP through the downstream effectors PKA, Epac1, and Epac2. A2AR agonism potentiated TNF-α inhibition by apremilast, consistent with the cAMP-elevating effects of that receptor. Because the A2AR is also involved in the anti-inflammatory effects of MTX, the mechanism of action of both drugs involves cAMP-dependent pathways and is therefore partially overlapping in nature. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0771-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4570588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45705882015-09-16 Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors Perez-Aso, Miguel Montesinos, M. Carmen Mediero, Aránzazu Wilder, Tuere Schafer, Peter H. Cronstein, Bruce Arthritis Res Ther Research Article INTRODUCTION: This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A(2A) receptors (A(2A)R). METHODS: After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10, IL-6 and IL-1α were measured in the Raw264.7 monocytic murine cell line. PKA, Epac1/2 (signaling intermediates for cAMP) and A(2A)R knockdowns were performed by shRNA transfection and interactions with A2AR and A2BR, as well as with methotrexate were tested in vitro and in the murine air pouch model. Statistical differences were determined using one or two-way ANOVA or Student’s t test. The alpha nominal level was set at 0.05 in all cases. A P value of < 0.05 was considered significant. RESULTS: In vitro, apremilast increased intracellular cAMP and inhibited TNF-α release (IC(50)=104nM) and the specific A(2A)R-agonist CGS21680 (1μM) increased apremilast potency (IC(50)=25nM). In this cell line, apremilast increased IL-10 production. PKA, Epac1 and Epac2 knockdowns prevented TNF-α inhibition and IL-10 stimulation by apremilast. In the murine air pouch model, both apremilast and MTX significantly inhibited leukocyte infiltration, while apremilast, but not MTX, significantly inhibited TNF-α release. The addition of MTX (1 mg/kg) to apremilast (5 mg/kg) yielded no more inhibition of leukocyte infiltration or TNF-α release than with apremilast alone. CONCLUSIONS: The immunoregulatory effects of apremilast appear to be mediated by cAMP through the downstream effectors PKA, Epac1, and Epac2. A2AR agonism potentiated TNF-α inhibition by apremilast, consistent with the cAMP-elevating effects of that receptor. Because the A2AR is also involved in the anti-inflammatory effects of MTX, the mechanism of action of both drugs involves cAMP-dependent pathways and is therefore partially overlapping in nature. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0771-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-15 2015 /pmc/articles/PMC4570588/ /pubmed/26370839 http://dx.doi.org/10.1186/s13075-015-0771-6 Text en © Perez-Aso et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Perez-Aso, Miguel Montesinos, M. Carmen Mediero, Aránzazu Wilder, Tuere Schafer, Peter H. Cronstein, Bruce Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors |
title | Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors |
title_full | Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors |
title_fullStr | Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors |
title_full_unstemmed | Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors |
title_short | Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors |
title_sort | apremilast, a novel phosphodiesterase 4 (pde4) inhibitor, regulates inflammation through multiple camp downstream effectors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570588/ https://www.ncbi.nlm.nih.gov/pubmed/26370839 http://dx.doi.org/10.1186/s13075-015-0771-6 |
work_keys_str_mv | AT perezasomiguel apremilastanovelphosphodiesterase4pde4inhibitorregulatesinflammationthroughmultiplecampdownstreameffectors AT montesinosmcarmen apremilastanovelphosphodiesterase4pde4inhibitorregulatesinflammationthroughmultiplecampdownstreameffectors AT medieroaranzazu apremilastanovelphosphodiesterase4pde4inhibitorregulatesinflammationthroughmultiplecampdownstreameffectors AT wildertuere apremilastanovelphosphodiesterase4pde4inhibitorregulatesinflammationthroughmultiplecampdownstreameffectors AT schaferpeterh apremilastanovelphosphodiesterase4pde4inhibitorregulatesinflammationthroughmultiplecampdownstreameffectors AT cronsteinbruce apremilastanovelphosphodiesterase4pde4inhibitorregulatesinflammationthroughmultiplecampdownstreameffectors |